MJardin Group, Inc. (CSE: MJAR) announced earlier this week that the company will begin trading the company’s common stock on the Canadian Securities Exchange, under the ticket symbol “MJAR.” Over the past few years, MJardin Group has assisted in the launch of 100 plus licensed cannabis cultivation facilities.
Their company has also successfully sold over 100,000kg of dried cannabis product. Their business model is centered around offering consulting services and creating partnerships with cannabis operators that hold valid licenses.
Also, in this this press release, MJardin has announced that the company has signed a binding LOI to acquire Canadian cannabis company GrowForce Holdings Inc. Headquarter in Toronto, GrowForce Holdings Inc. is an indoor cannabis cultivator that operates under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).
The combined entity would own 49 operating facilities including 23 cultivation, 5 extraction, two outdoor cultivation grows, and 19 retail cannabis dispensaries located across the United States and Canada. In 2019, MJardin Group plans to take their company’s operations to new countries and this acquisition will be integral in assisting the company do so.
“Listing on the Canadian Securities Exchange is a significant milestone in our evolution and a testament to our team’s dedication and focus on building a preeminent global cannabis management platform. As we enter the public markets, we believe that MJardin is well positioned for continued growth in the U.S. and Canada, as well as international expansion in Europe, Africa and Latin America,” said Rishi Gautam, Chairman & Chief Executive Officer of MJardin.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…